Titre : Troubles du contrôle des impulsions

Troubles du contrôle des impulsions : Questions médicales fréquentes

Termes MeSH sélectionnés :

Early Detection of Cancer
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Troubles du contrôle des impulsions : Questions médicales les plus fréquentes", "headline": "Troubles du contrôle des impulsions : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Troubles du contrôle des impulsions : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-17", "dateModified": "2025-04-13", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Troubles du contrôle des impulsions" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Troubles mentaux", "url": "https://questionsmedicales.fr/mesh/D001523", "about": { "@type": "MedicalCondition", "name": "Troubles mentaux", "code": { "@type": "MedicalCode", "code": "D001523", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F03" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Pyromanie", "alternateName": "Firesetting Behavior", "url": "https://questionsmedicales.fr/mesh/D005391", "about": { "@type": "MedicalCondition", "name": "Pyromanie", "code": { "@type": "MedicalCode", "code": "D005391", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F03.250.300" } } }, { "@type": "MedicalWebPage", "name": "Jeu de hasard", "alternateName": "Gambling", "url": "https://questionsmedicales.fr/mesh/D005715", "about": { "@type": "MedicalCondition", "name": "Jeu de hasard", "code": { "@type": "MedicalCode", "code": "D005715", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F03.250.400" } } }, { "@type": "MedicalWebPage", "name": "Trichotillomanie", "alternateName": "Trichotillomania", "url": "https://questionsmedicales.fr/mesh/D014256", "about": { "@type": "MedicalCondition", "name": "Trichotillomanie", "code": { "@type": "MedicalCode", "code": "D014256", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F03.250.800" } } } ], "about": { "@type": "MedicalCondition", "name": "Troubles du contrôle des impulsions", "alternateName": "Disruptive, Impulse Control, and Conduct Disorders", "code": { "@type": "MedicalCode", "code": "D007174", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "23andMe, Sunnyvale, California, USA." } }, { "@type": "Person", "name": "Ana Marques", "url": "https://questionsmedicales.fr/author/Ana%20Marques", "affiliation": { "@type": "Organization", "name": "EA 7280 Laboratory of Neuropychopharmacology of the Subcortical Dopaminergic Systems, UFR Medecine, Université Clermont Auvergne, Clermont-Ferrand, France." } }, { "@type": "Person", "name": "Pedro M Paz-Alonso", "url": "https://questionsmedicales.fr/author/Pedro%20M%20Paz-Alonso", "affiliation": { "@type": "Organization", "name": "Basque Center on Cognition, Brain and Language (BCBL), San Sebastián, Spain. Electronic address: p.pazalonso@bcbl.eu." } }, { "@type": "Person", "name": "Manuel Delgado-Alvarado", "url": "https://questionsmedicales.fr/author/Manuel%20Delgado-Alvarado", "affiliation": { "@type": "Organization", "name": "Neurodegenerative Disorders Area, Biodonostia Health Research Institute, San Sebastián, Spain; Neurology Department, Sierrallana Hospital, Torrelavega, Spain; IDIVAL, Valdecilla Biomedical Research Institute, Santander, Spain; Biomedical Research Networking Center for Mental Health (CIBERSAM), Madrid, Spain. Electronic address: manueldelgadoalv@gmail.com." } }, { "@type": "Person", "name": "Maria Livia Fantini", "url": "https://questionsmedicales.fr/author/Maria%20Livia%20Fantini", "affiliation": { "@type": "Organization", "name": "EA 7280 Laboratory of Neuropychopharmacology of the Subcortical Dopaminergic Systems, UFR Medecine, Université Clermont Auvergne, Clermont-Ferrand, France. mfantini@chu-clermontferrand.fr." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Pathological and oncological outcomes of pylorus-preserving versus conventional distal gastrectomy in early gastric cancer: a systematic review and meta-analysis.", "datePublished": "2022-09-24", "url": "https://questionsmedicales.fr/article/36153587", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12957-022-02766-0" } }, { "@type": "ScholarlyArticle", "name": "Ornithine aminotransferase and carbamoyl phosphate synthetase 1 involved in ammonia metabolism serve as novel targets for early stages of gastric cancer.", "datePublished": "2022-09-13", "url": "https://questionsmedicales.fr/article/36098904", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jcla.24692" } }, { "@type": "ScholarlyArticle", "name": "Patient characteristics and health system factors associated with adjuvant radiation therapy receipt in older women with early-stage endometrial cancer.", "datePublished": "2022-09-08", "url": "https://questionsmedicales.fr/article/36088216", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jgo.2022.08.020" } }, { "@type": "ScholarlyArticle", "name": "Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer.", "datePublished": "2022-07-15", "url": "https://questionsmedicales.fr/article/35856081", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s43856-022-00155-y" } }, { "@type": "ScholarlyArticle", "name": "Early Mortality among Patients with Head and Neck Cancer Diagnosed in Thuringia, Germany, between 1996 and 2016-A Population-Based Study.", "datePublished": "2022-06-24", "url": "https://questionsmedicales.fr/article/35804871", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/cancers14133099" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Troubles mentaux", "item": "https://questionsmedicales.fr/mesh/D001523" }, { "@type": "ListItem", "position": 3, "name": "Troubles du contrôle des impulsions", "item": "https://questionsmedicales.fr/mesh/D007174" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Troubles du contrôle des impulsions - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Troubles du contrôle des impulsions", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Troubles du contrôle des impulsions", "description": "Comment diagnostique-t-on un trouble du contrôle des impulsions ?\nQuels critères sont utilisés pour le diagnostic ?\nLes tests psychologiques sont-ils nécessaires ?\nQui peut poser le diagnostic ?\nLes antécédents familiaux influencent-ils le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D007174?mesh_terms=Early+Detection+of+Cancer&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Troubles du contrôle des impulsions", "description": "Quels sont les symptômes courants des troubles du contrôle des impulsions ?\nComment se manifeste l'impulsivité ?\nY a-t-il des signes d'alerte précoce ?\nLes troubles de l'humeur sont-ils liés ?\nLes symptômes varient-ils selon l'âge ?", "url": "https://questionsmedicales.fr/mesh/D007174?mesh_terms=Early+Detection+of+Cancer&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Troubles du contrôle des impulsions", "description": "Peut-on prévenir les troubles du contrôle des impulsions ?\nQuel rôle joue l'éducation dans la prévention ?\nLes programmes de sensibilisation sont-ils efficaces ?\nComment les parents peuvent-ils aider ?\nLe soutien scolaire joue-t-il un rôle ?", "url": "https://questionsmedicales.fr/mesh/D007174?mesh_terms=Early+Detection+of+Cancer&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Troubles du contrôle des impulsions", "description": "Quels traitements sont disponibles pour ces troubles ?\nLa thérapie cognitive est-elle efficace ?\nLes médicaments peuvent-ils aider ?\nLa thérapie de groupe est-elle bénéfique ?\nCombien de temps dure le traitement ?", "url": "https://questionsmedicales.fr/mesh/D007174?mesh_terms=Early+Detection+of+Cancer&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Troubles du contrôle des impulsions", "description": "Quelles complications peuvent survenir ?\nLes troubles de l'humeur sont-ils des complications possibles ?\nComment les comportements à risque affectent-ils la vie ?\nLes relations sociales sont-elles affectées ?\nY a-t-il un risque accru de toxicomanie ?", "url": "https://questionsmedicales.fr/mesh/D007174?mesh_terms=Early+Detection+of+Cancer&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Troubles du contrôle des impulsions", "description": "Quels sont les facteurs de risque principaux ?\nLe stress peut-il aggraver ces troubles ?\nL'environnement familial joue-t-il un rôle ?\nLes troubles de l'attention sont-ils un facteur de risque ?\nL'âge d'apparition influence-t-il le risque ?", "url": "https://questionsmedicales.fr/mesh/D007174?mesh_terms=Early+Detection+of+Cancer&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on un trouble du contrôle des impulsions ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'évaluation clinique des symptômes et l'historique du patient." } }, { "@type": "Question", "name": "Quels critères sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les critères incluent des comportements impulsifs récurrents et des conséquences négatives." } }, { "@type": "Question", "name": "Les tests psychologiques sont-ils nécessaires ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des tests peuvent être utilisés pour évaluer la gravité des symptômes et l'impact fonctionnel." } }, { "@type": "Question", "name": "Qui peut poser le diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Un psychiatre ou un psychologue qualifié peut poser le diagnostic après évaluation." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les antécédents familiaux de troubles mentaux peuvent être un facteur de risque." } }, { "@type": "Question", "name": "Quels sont les symptômes courants des troubles du contrôle des impulsions ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent l'agressivité, l'irritabilité et des comportements destructeurs." } }, { "@type": "Question", "name": "Comment se manifeste l'impulsivité ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "L'impulsivité se manifeste par des actions sans réflexion préalable, souvent regrettées après." } }, { "@type": "Question", "name": "Y a-t-il des signes d'alerte précoce ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des accès de colère fréquents ou des comportements à risque peuvent alerter." } }, { "@type": "Question", "name": "Les troubles de l'humeur sont-ils liés ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les troubles de l'humeur peuvent coexister avec des troubles du contrôle des impulsions." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de l'âge et du développement psychologique." } }, { "@type": "Question", "name": "Peut-on prévenir les troubles du contrôle des impulsions ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est possible par l'éducation et le soutien émotionnel dès le jeune âge." } }, { "@type": "Question", "name": "Quel rôle joue l'éducation dans la prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "L'éducation aide à développer des compétences de gestion des émotions et des comportements." } }, { "@type": "Question", "name": "Les programmes de sensibilisation sont-ils efficaces ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les programmes de sensibilisation peuvent réduire les comportements à risque chez les jeunes." } }, { "@type": "Question", "name": "Comment les parents peuvent-ils aider ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Les parents peuvent aider en établissant des règles claires et en offrant un soutien affectif." } }, { "@type": "Question", "name": "Le soutien scolaire joue-t-il un rôle ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un soutien scolaire adéquat peut aider à prévenir les comportements impulsifs chez les enfants." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour ces troubles ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la thérapie comportementale et, parfois, des médicaments." } }, { "@type": "Question", "name": "La thérapie cognitive est-elle efficace ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la thérapie cognitive aide à modifier les pensées et comportements impulsifs." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils aider ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme les antidépresseurs peuvent être prescrits pour réduire les symptômes." } }, { "@type": "Question", "name": "La thérapie de groupe est-elle bénéfique ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la thérapie de groupe offre un soutien et des stratégies de gestion des impulsions." } }, { "@type": "Question", "name": "Combien de temps dure le traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La durée du traitement varie selon la gravité des symptômes et la réponse au traitement." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des problèmes relationnels, juridiques et des troubles associés." } }, { "@type": "Question", "name": "Les troubles de l'humeur sont-ils des complications possibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les troubles de l'humeur comme la dépression peuvent survenir en raison de l'impulsivité." } }, { "@type": "Question", "name": "Comment les comportements à risque affectent-ils la vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les comportements à risque peuvent entraîner des blessures, des problèmes juridiques et des regrets." } }, { "@type": "Question", "name": "Les relations sociales sont-elles affectées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les troubles du contrôle des impulsions peuvent nuire aux relations interpersonnelles." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de toxicomanie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes avec ces troubles peuvent avoir un risque accru de développer des addictions." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque principaux ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, des traumatismes et des troubles mentaux." } }, { "@type": "Question", "name": "Le stress peut-il aggraver ces troubles ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut exacerber les symptômes des troubles du contrôle des impulsions." } }, { "@type": "Question", "name": "L'environnement familial joue-t-il un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un environnement familial instable peut augmenter le risque de développer ces troubles." } }, { "@type": "Question", "name": "Les troubles de l'attention sont-ils un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les troubles de l'attention peuvent coexister et augmenter le risque d'impulsivité." } }, { "@type": "Question", "name": "L'âge d'apparition influence-t-il le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une apparition précoce des symptômes peut indiquer un risque accru de complications." } } ] } ] }

Sources (10000 au total)

Pathological and oncological outcomes of pylorus-preserving versus conventional distal gastrectomy in early gastric cancer: a systematic review and meta-analysis.

Pylorus-preserving gastrectomy (PPG) is a function-preserving surgery for the treatment of early gastric cancer (EGC) in the middle third of the stomach. According to the literature reports, PPG decre... The protocol was registered in PROSPERO under number CRD42022304677. Databases including PubMed, Embase, Web of Science, and the Cochrane Register of Controlled Trials were searched before February 21... A total of 4500 patients from 16 studies were included. Compared with the CDG group, the PPG group had fewer lymph nodes harvested (WMD= -3.09; 95% CI -4.75 to -1.43; P < 0.001). Differences in the nu... The meta-analysis of existing evidence demonstrated that the survival outcomes of PPG may be comparable to those of CDG. However, fewer lymph nodes at stations in No. 5, No. 6, No. 9, and No. 11p were...

Ornithine aminotransferase and carbamoyl phosphate synthetase 1 involved in ammonia metabolism serve as novel targets for early stages of gastric cancer.

The sensitivity and specificity of current biomarkers for gastric cancer were insufficient. The aim of the present study was to screen novel biomarkers and determine the diagnostic values of ornithine... With stable isotope tags, we labelled an initial discovery group of four paired gastric cancer tissue samples and identified with LC-ESI-MS/MS. A validation group of 159 gastric cancer samples and 30 ... Four hundred and thirty one proteins were found differentially expressed in gastric cancer tissues. Of these proteins, OAT and CPS1 were found over-expressed in gastric cancer patients, with sensitivi... The present findings indicated a tight correlation between the co-expression of OAT and CPS1 and the histological grade, local invasion, and TNM stages of gastric cancer. Therefore, OAT and CPS1 might...

Patient characteristics and health system factors associated with adjuvant radiation therapy receipt in older women with early-stage endometrial cancer.

Among women with early-stage endometrial cancer (EC), age, stage, grade, and histology are used to determine fitness for adjuvant radiation therapy (RT) administration. We examined non-cancer factors ... Using data from the Surveillance Epidemiology and End Results cancer registry program linked with Medicare claims, we identified 25,654 women (aged ≥66 years) diagnosed with first primary stage I-II E... Adjuvant RT was less commonly administered to Asian American and Pacific Islander patients than non-Hispanic White patients (Prevalence ratio [PR], 0.84; 95% confidence interval [CI], 0.73 to 0.97). C... Findings suggest that various non-cancer factors affect the delivery of adjuvant RT to older women with early-stage EC in real-world oncology practice. Advancing our understanding of factors associate...

Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer.

Treatment for metastatic colorectal cancer patients beyond the second line remains challenging, highlighting the need for early phase trials of combination therapies for patients who had disease progr... MORPHEUS-CRC is an umbrella, multicenter, open-label, phase Ib/II, randomized, controlled trial (NCT03555149), with active experimental arms ongoing. Patients enrolled were assigned to a control arm (... The experimental arm showed no efficacy signal, yet a well-tolerated safety profile in the MORPHEUS-CRC trial. Treatment effects estimated in hybrid control design were comparable to those in the MORP... Hybrid control provides comparable treatment-effect estimates with generally improved precision, and thus can be of value to inform early-phase clinical development in metastatic colorectal cancer....

Construction and validation of N6-methyladenosine long non-coding RNAs signature of prognostic value for early biochemical recurrence of prostate cancer.

Early biochemical recurrence (eBCR) indicated a high risk for potential recurrence and metastasis in prostate cancer. The N6-methyladenosine (m6A) methylation modification played an important role in ... Pearson correlation analysis was first conducted to explore m6A lncRNAs and univariate Cox regression analysis was further performed to identify m6A lncRNAs of prognostic roles for predicting eBCR in ... Five hundred and thirty-eighth m6A lncRNAs were searched out through Pearson correlation analysis and 25 out of 538 m6A lncRNAs were identified to pose prediction roles for eBCR in prostate cancers. A... The m6A lncRNA signature in this study could be utilized to efficiently predict eBCR occurrence, various clinical characteristic and immune microenvironment for prostate cancer....

MRI characteristics of breast edema for assessing axillary lymph node burden in early-stage breast cancer: a retrospective bicentric study.

To investigate whether breast edema characteristics at preoperative T2-weighted imaging (T2WI) could help evaluate axillary lymph node (ALN) burden in patients with early-stage breast cancer.... This retrospective study included women with clinical T1 and T2 stage breast cancer and preoperative MRI examination in two independent cohorts from May 2014 to December 2020. Low (< 3 LNs+) and high ... A total of 1092 patients were included in this study. BES was identified as the independent predictor of pALN burden in primary (n = 677) and validation (n = 415) cohorts. The analysis using MRI-ALN s... In individuals with early-stage breast cancer, preoperative MRI characteristics of breast edema could be a promising predictor for pALN burden, which may aid in treatment planning.... • In this retrospective study of 1092 patients with early-stage breast cancer from two cohorts, the MRI characteristic of breast edema has independent and additive predictive value for assessing axill...

A Clinical Diagnostic Value Analysis of Serum CA125, CA199, and HE4 in Women with Early Ovarian Cancer: Systematic Review and Meta-Analysis.

To evaluate the value of combined detection of serum CA125, CA199, and HE4 in the diagnosis of ovarian cancer.... Relevant articles retrieved from PubMed, Elsevier Science, Springer, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP databases were screened strictly according to inclusion and exclus... The results of meta-analysis showed that there was a statistical difference in diagnostic specificity analysis of CA125 (OR = 1.91, 95% CI (1.58, 2.32),... In the clinical assisted diagnosis of ovarian cancer, combined detection of CA125, CA199, and HE4 has the stronger discriminant ability and higher accuracy than single detection of CA125, which can im...

BMI increase during early childhood in boys with cystic fibrosis and early adrenarche.

Increase in body mass index (BMI) in early childhood (1-6 years) was found to be a contributing factor for impaired final height in boys with Cystic Fibrosis (CF). Early adrenarche (before age 9 years... Boys with CF, aged 8-9 years, visiting the CF expertize center Utrecht were included. Since 2018, anthropomorphic, pubertal and endocrine data were collected. Early adrenarche in boys was defined as a... Thirteen boys (mean age 8.55 ± 0.27 years) were enrolled. The median (IQR) DHEAS-level was 1.3 µmol/L (0.71-2.40). Eight boys (61.5%) had an early rise in DHEAS-levels ≥ 1 µmol/L. Mean increase in BMI... In this small cohort, 61.5% of boys with CF between 8 and 9 years had an early rise of DHEAS, which was correlated to ΔBMI...